- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03626662
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
October 17, 2023 updated by: Amgen
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)].
AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
79
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Clinical Medical and Analytical eXellence CMAX
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Linear Clinical Research Limited
-
-
-
-
California
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Excel Medical Clinical Trials
-
Jacksonville, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
South Miami, Florida, United States, 33143
- QPS Miami Research Associates
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
New York
-
New York, New York, United States, 10016
- New York University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Medpace Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and women with ages between 18 and 70 years old, inclusive.
- Protocol-defined elevated plasma Lp(a) level.
- Body mass index (BMI) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening.
- Women must be of non-reproductive potential.
- Other Inclusion criteria may apply
Exclusion Criteria:
- Currently receiving treatment in another investigational device or drug study.
- Women who are lactating/breastfeeding or who plan to breastfeed while on study or through 90 days after receiving the last dose of investigational product (for subjects who withdraw prior to end of study).
- History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
- History or clinical evidence of bleeding diathesis or any coagulation disorder.
- History or clinical evidence of peripheral neuropathy.
- Other Exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Single Ascending Dose Cohorts
|
Calculated volume to match experimental drug.
|
Experimental: AMG 890
Single Ascending Dose Cohorts
|
Ascending Single Doses of AMG 890
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject incidence of treatment-emergent adverse events
Time Frame: up to 365 days
|
up to 365 days
|
|
Changes in blood pressure
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group.
|
Up to 365 days
|
Changes in heart rate
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in respiratory rate
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group.
|
Up to 365 days
|
Changes in temperature
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group.
|
Up to 365 days
|
Changes in QRS interval
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group.
|
Up to 365 days
|
Changes in PR interval
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in QT interval
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group.
|
Up to 365 days
|
Changes in RR interval
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in red blood cells
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in platelets
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in white blood cells
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in prothrombin time (PT)
Time Frame: Up to 365 days
|
Up to 365 days
|
|
Changes in international normalized ratio (INR)
Time Frame: Up to 365 days
|
Up to 365 days
|
|
Changes in activated partial thromboplastin time (aPTT)
Time Frame: Up to 365 days
|
Up to 365 days
|
|
Changes in Thrombin time (TT)
Time Frame: Up to 365 days
|
Up to 365 days
|
|
Changes in aspartate aminotransferase (AST) levels (units: U/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in alanine aminotransferase (ALT) levels (units: U/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in total bilirubin levels (units: μmol/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in direct bilirubin levels (units: μmol/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in alkaline phosphatase levels (units: U/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in total protein levels (units: g/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Changes in albumin levels (units: g/L)
Time Frame: Up to 365 days
|
The analysis will include summary statistics at selected time points by treatment group
|
Up to 365 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics parameter of maximum observed concentration (Cmax)
Time Frame: up to 365 days
|
up to 365 days
|
Pharmacokinetics parameter of time of maximum observed concentration (tmax)
Time Frame: up to 365 days
|
up to 365 days
|
Pharmacokinetics parameter of area under the concentration time curve (AUC)
Time Frame: up to 365 days
|
up to 365 days
|
Change in plasma Lp(a) over time
Time Frame: Up to 365 days
|
Up to 365 days
|
Percent change in plasma Lp(a) over time
Time Frame: Up to 365 days
|
Up to 365 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 30, 2018
Primary Completion (Actual)
April 18, 2023
Study Completion (Actual)
April 18, 2023
Study Registration Dates
First Submitted
June 19, 2018
First Submitted That Met QC Criteria
August 9, 2018
First Posted (Actual)
August 13, 2018
Study Record Updates
Last Update Posted (Actual)
October 18, 2023
Last Update Submitted That Met QC Criteria
October 17, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20170544
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities.
There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).
In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling.
Requests are reviewed by a committee of internal advisors.
If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision.
Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.
This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications.
Further details are available at the URL below.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
-
Penn State UniversityCalifornia Walnut CommissionCompletedCardiovascular DiseaseUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States